Contents
1. The overview of “Teva Pharmaceuticals”
2. The detailed data of “Teva Pharmaceuticals”
3. The map of “Teva Pharmaceuticals”
4. The stock weekly chart of “Teva Pharmaceuticals”
5. The stock weekly trading radar of “Teva Pharmaceuticals”
6. The annual filings of “Teva Pharmaceuticals”
7. The stock price of “Teva Pharmaceuticals”
* Last update: February 10, 2022
The overview of “Teva Pharmaceuticals”
“Teva Pharmaceutical Industries Ltd.“, founded in 1901, is a global pharmaceutical company with headquarters in Petah Tikva, Israel. It was given the current name on May 1, 1935. The company’s facilities are located in Israel, North America, South America, Europe, and Australia, and it specializes in generic drugs, business for pharmaceutical ingredients and proprietary pharmaceuticals. Also, it’s the eighteenth largest pharmaceutical company in the world.
In 2000, “Teva Pharmaceuticals” acquired Canada-based “Novopharm”, German generic “Ratiopharm” for 5 billion USD in August 2010, US-biopharmaceutical company “Cephalon” for 6.8 billion USD in May 2011, and Japanese generic drug company “Taiyo Pharmaceutical Industry” for 40 billion JPY in the same year. The company’s stocks are listed on not only the Tel Aviv Stock Exchange, but also the New York Stock Exchange (NYSE).
The detailed data of “Teva Pharmaceuticals”
●Established date： 1901
●Location： 5 Basel St, Petach Tikva 49131, Israel
●Stock Exchange： NYSE（TEVA）
●Listing date： 2012
●Business details： Development and marketing of drugs（Biotechnlogy）
●Official website：
・https://www.teva.co.il/
・https://www.tevapharm.com/
The map of “Teva Pharmaceuticals”
The stock weekly chart of “Teva Pharmaceuticals”
The stock weekly trading radar of “Teva Pharmaceuticals”
The annual filings of “Teva Pharmaceuticals”
* Date: Feb 21, 2020
* Date: Feb 19, 2019
* U.S. dollars in millions
| Cutoff date | December 31, 2020 | December 31, 2019 | December 31, 2018 | December 31, 2017 |
|---|---|---|---|---|
| Operating income | (3,572) | (443) | (1,637) | (17,484) |
| Net income attributable | (3,990) | (999) | (2,399) | (16,525) |
| Total current assets | 13,005 | 13,464 | 13,794 | 15,382 |
| Total current liabilities | 13,164 | 13,674 | 14,322 | 17,921 |
| Current ratio (1.2 or more is the best) | 0.99 | 0.98 | 0.96 | 0.86 |
| Common stock and additional paid-in capital | 27,500 | 27,368 | 27,266 | 23,533 |
| Treasury stock | (4,128) | (4,128) | (4,142) | (4,149) |
| Retained earning, Accumulated deficit | (10,946) | (6,956) | (5,958) | (3,803) |
| Total stockholders' equity | 11,061 | 15,063 | 15,794 | 18,745 |
| Total equity and liabilities | 50,640 | 57,470 | 60,683 | 70,615 |
| Equity ratio (20% or more is better) (50% or more is the best) | 21.84% | 26.21% | 26.03% | 26.55% |
| Cash flows from operating activities | 1,216 | 748 | 2,446 | 2,225 |
| Cash flows from investing activities | 863 | 1,355 | 1,866 | 3,446 |
| Cash flows from financing activities | (1,885) | (1,926) | (3,351) | (5,750) |
| Free cash flow | 2,079 | 2,103 | 4,312 | 5,671 |
The stock price of “Teva Pharmaceuticals”
Loss from operations expanded and Accumulated deficit increased.
Equity ratio declined, but it's not bad situation because of more than 20%.
As much as possible, it might be better that Current ratio are raised in order to aim Retained earning.
Also, the comapny sells a part of the assets for 3 years in a row, but Free cash flow keeps to decend still.
We are also concerned about the fact.
The stock price of "Teva Pharmaceuticals" in 2021 might tend to be stagnant as well as 2020.
* Comment
Net income expanded, but it's a negative value yet.
Whereas, Accumulated deficit increased.
Also, Free cash flow decended.
However, Equity ratio is not bad situation because of more than 20%.
The stock price of "Teva Pharmaceuticals" in 2020 might tend to decend or be stagnant as well as 2019.
* Comment
Net income expanded, but it's a negative value yet.
Whereas, Accumulated deficit increased.
Also, Free cash flow decended.
On the other hand, Current ratio rose a little.
Also, Equity ratio hardly change and it's common situation.
| Term year | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Entity min stock price in monthly chart | N/A | approx 8.00 (Dec) | approx 8.60 (Apr) | approx 6.86 (Sep) | approx 15.42 (Dec) |
| Entity max stock price in monthly chart | N/A | approx 11.90 (Feb) | approx 12.60 (Jun) | approx 20.04 (Feb) | approx 24.35 (Jun) |
| Stock price increase ratio (50% or more is the best) | N/A | (48.75)% | 46.50% | (192.12)% | (57.91)% |
